Stay updated on TEPEZZA Post-Marketing Requirement Study Clinical Trial

Sign up to get notified when there's something new on the TEPEZZA Post-Marketing Requirement Study Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the TEPEZZA Post-Marketing Requirement Study Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T21:25:28.000Z thumbnail image
  3. Check
    2 days ago
    No Change Detected
  4. Check
    3 days ago
    No Change Detected
  5. Check
    4 days ago
    No Change Detected
  6. Check
    9 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the number of infusions of teprotumumab in the treatment plan for Thyroid Eye Disease (TED) participants in the Phase 3b/4 trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:24:27.000Z thumbnail image
  7. Check
    23 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, such as age range, health conditions, and prior treatments, replacing the previous placeholder text that indicated no information was provided.
    Difference
    34%
    Check dated 2024-05-22T21:01:46.000Z thumbnail image
  8. Check
    40 days ago
    Change Detected
    Summary
    The value (Estimated) on the webpage has recently changed to . This change represents an update in the estimated completion date for the Phase 4 clinical trial evaluating the safety and tolerability of different dosing durations of Teprotumumab in patients with Thyroid Eye Disease.
    Difference
    0.0%
    Check dated 2024-05-06T14:33:26.000Z thumbnail image
  9. Check
    42 days ago
    Change Detected
    Summary
    The value 04 05 04 04 04 05 04 has recently changed to 05 03 05 02 (Estimated) 05 03 05. This change likely represents an update in the dosing durations of Teprotumumab in the treatment of Thyroid Eye Disease (TED) in adult participants in an international Phase 3b/4 trial.
    Difference
    0.6%
    Check dated 2024-05-04T09:36:35.000Z thumbnail image
  10. Check
    45 days ago
    Change Detected
    Difference
    0.8%
    Check dated 2024-04-30T22:18:01.000Z thumbnail image

Stay in the know with updates to TEPEZZA Post-Marketing Requirement Study Clinical Trial

Enter your email address, and we'll notify you when there's something new on the TEPEZZA Post-Marketing Requirement Study Clinical Trial page.